Tango Therapeutics, Inc. TNGX R2K

Healthcare · Biotechnology · United States

https://www.tangotx.com

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Market & Price

Market Cap

$3.18B

Current Price

$21.98

High / Low (52W)

$27.77 / $2.22

Beta

1.22

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$2.55

Price to Book

8.63

P/S

55.79

EV/EBITDA

-24.54

Dividend Yield

Profitability & Returns

ROCE

-29.52%

ROE

-38.42%

ROA

-20.69%

Profit Margin

Op Margin

EPS (Latest Qtr)

$-0.32

EPS (TTM)

$-0.83

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

26.51

Current Ratio

27.38

Debt

$32.79M

Total Assets

$398.69M

Current Assets

$353.76M

Working Capital

$332.08M

Ownership

Promoter Holding

1.38%

Chg in Prom Hold

FII / Inst Holding

127.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$2.83B

Total Revenue (TTM)

$56.99M

EBITDA

$-115.41M

Free Cash Flow

$-68.23M

Operating Cash Flow

$-141.55M

Shares Outstanding

144.65M

Gross Margin

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

35.89%

Profit 5Y

2.03%

Revenue (YoY)

Earnings (YoY)

PROS

Compounding revenue at 35.9% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TNGX Tango Therapeutics, Inc. R2K	21.98	-	$3.18B	-	-29.52%	-38.42%	35.89%	2.03%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-11.26M	6.39M	18.15M	6.79M	5.76M	5.77M	6.92M	5.77M	14.60M	10.73M	6.47M	19.88M	11.61M	5.39M	3.18M	53.81M	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.92M	44.15M	39.74M	41.86M	48.77M
Operating Income	-	-	-26.76M	-12.08M	-4.56M	-19.57M	-25.38M	-25.20M	-29.92M	-30.29M	-23.25M	-25.63M	-42.26M	-29.55M	-32.88M	-42.53M	-40.97M	14.07M	-41.86M	-48.77M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41.91M	-40.34M	14.63M	-41.38M	-48.31M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-39.84M	-38.82M	15.87M	-38.80M	-45.51M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34.00K	35.00K	-10.00K	-55.00K	1.00K
Net Income	-7.91M	-8.39M	-26.80M	-12.11M	-4.49M	-19.59M	-25.21M	-24.86M	-29.05M	-28.01M	-20.71M	-22.26M	-37.91M	-25.55M	-29.17M	-39.88M	-38.85M	15.88M	-38.75M	-45.51M
Diluted EPS	-	-	-	-	-0.09	-0.28	-0.29	-0.28	-0.33	-0.32	-0.23	-0.23	-0.35	-0.24	-0.27	-0.36	-0.35	0.13	-0.29	-0.32
R&D Expense	-	-	12.98M	15.00M	19.08M	21.92M	24.33M	23.74M	28.74M	28.04M	28.67M	27.15M	38.06M	38.65M	33.26M	36.44M	32.81M	30.82M	-	33.53M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	7.66M	-	24.86M	36.53M	42.07M	62.38M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	135.93M	150.70M	187.66M	173.67M
Operating Income	-52.20M	-	-111.07M	-114.17M	-145.59M	-111.29M
EBITDA	-	-	-109.46M	-111.76M	-143.10M	-109.01M
Interest Expense	-	-	-	-	-	-
Pretax Income	-	-	-108.12M	-101.61M	-130.09M	-101.59M
Tax Provision	-	-	54.00K	134.00K	208.00K	4.00K
Net Income	-51.97M	-	-108.18M	-101.74M	-130.30M	-101.59M
Diluted EPS	-	-0.94	-1.23	-1.08	-1.19	-
R&D Expense	49.99M	77.64M	105.91M	115.20M	143.92M	132.16M

Compounded Sales Growth

5 Years:	35.89%
1 Year:	-

Compounded Profit Growth

5 Years:	2.03%
1 Year:	-

Stock Price Performance

1 Year:	+890.09%
6 Months:	+107.95%
3 Months:	+97.31%
1 Month:	-0.36%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	207.25M	-	436.47M	402.57M	316.49M	398.69M
Current Assets	-	-	-	375.27M	346.54M	266.34M	353.76M
Cash & Equivalents	-	28.38M	-	59.97M	66.39M	69.53M	112.28M
Inventory	-	-	-	-	-	-	-
Receivables	-	-	2.00M	2.00M	0	-	-
Total Liabilities	-	168.65M	-	186.99M	149.46M	116.97M	52.51M
Current Liabilities	-	40.92M	-	55.55M	45.94M	38.17M	21.68M
Long Term Debt	-	-	-	-	-	-	-
Total Debt	-	-	-	41.13M	38.92M	36.49M	33.57M
Total Equity	7.91M	38.60M	-	249.48M	253.11M	199.52M	346.18M
Shares Outstanding	-	-	-	88.18M	102.20M	107.73M	135.94M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	70.07M	-	-109.08M	-117.98M	-131.50M	-138.89M
Investing Cash Flow	-145.47M	-	26.40M	41.43M	86.13M	-40.87M
Financing Cash Flow	80.88M	-	1.61M	82.41M	47.66M	222.50M
Capital Expenditure	-1.11M	-	-7.69M	-1.53M	-754.00K	-1.05M
Free Cash Flow	68.97M	-	-116.77M	-119.51M	-132.25M	-139.93M
Net Change in Cash	-	-	-81.07M	5.85M	2.29M	42.75M

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-681.8%	-	-446.8%	-312.6%	-346.1%	-178.4%
Net Margin %	-678.8%	-	-435.1%	-278.5%	-309.7%	-162.9%
ROE %	-134.6%	-	-43.4%	-40.2%	-65.3%	-29.3%
ROCE %	-31.4%	-	-29.2%	-32.0%	-52.3%	-29.5%

Shareholding Pattern

Insiders

1.38%

Institutions

127.00%

Public Float

128.78%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	RTW Investments LP	9.20%	13.30M	$292.35M
2	Adage Capital Partners GP L.L.C.	8.86%	12.81M	$281.55M
3	Boxer Capital Management, LLC	7.52%	10.88M	$239.06M
4	TCG Crossover Management, LLC	7.28%	10.53M	$231.47M
5	FMR, LLC	6.85%	9.91M	$217.73M
6	Farallon Capital Management LLC	6.29%	9.10M	$199.96M
7	Blackrock Inc.	6.05%	8.75M	$192.28M
8	Woodline Partners LP	5.53%	8.00M	$175.84M
9	Nextech Invest, Ltd.	5.02%	7.27M	$159.71M
10	TRV GP IV, LLC	4.41%	6.37M	$140.11M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TNGX

No recent headlines available.

TNGX · Healthcare